Kennewick, WA – October 21, 2026 – Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, today provided an update on the clinical trial activation process for RadioGel® at Mayo Clinic.
We have achieved another key milestone in Mayo Clinic’s clinical trial activation process for RadioGel®. The Mayo Clinic Research Protocol Specialist has formally approved all required documentation following a successful document analysis phase. With this key administrative approval secured, the study has now officially advanced into the formal Site Assessment phase, bringing us one step closer to clinical initiation.
We are working with our Office of Clinical Trials facilitator from the Mayo Clinic to move through the process as expeditiously as possible. The facilitator will help coordinate timelines and related activities as we progress through the remaining stages of study activation.
We are working directly with our dedicated facilitator within Mayo Clinic Office of Clinical Trials to accelerate this next phase. This close collaboration ensures synchronized timelines and streamlines logistics as we push toward the final stages of study activation and site initiation.
We remain fully aligned with Mayo Clinic’s procedural standards, executing all data and material requests with high efficiency. Our overriding priority is to deliver a medical device of the highest caliber while ensuring all clinical staff are comprehensively trained and rigorous radioactive handling protocols are firmly in place. This absolute focus on quality and safety ensures the trial is positioned to achieve the best possible outcomes for patients.
The Company will continue to provide updates to shareholders as material developments occur throughout the activation process.
About Vivos Inc.
Vivos Inc. is developing advanced Yttrium-90 based brachytherapy devices for the treatment of tumors in both animals (IsoPet ® ) and humans (RadioGel ® ). The Company is committed to delivering safer, more effective, and accessible cancer therapies through Precision Radionuclide Therapy™.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of applicable securities laws. Actual results may differ materially from those expressed or implied due to various risks and uncertainties.
Contact: Vivos Inc. Investor Relations | investors@vivosinc.com




